Type 1 Diabetes, Type 2 Diabetes
Conditions
Brief summary
This six center international study will include two United Kingdom National Health Service centers, two centers in Melbourne, Australia and one center each in Denmark and Spain. The objective of the study is to evaluate subject acceptance of the a new insulin pump and transmitter together with the accompanying training materials. Descriptive data from participant questionnaires and device uploads will be evaluated. Pediatric subjects between the ages of 7 - 18 years and adults from the age of 19 years of age upwards, who currently use an insulin pump in the management of their type 1 or type 2 diabetes, will be invited to participate. Each subject will be trained on the study device and then use it for approximately six weeks. During this time there will be three in-clinic visits and four follow-up phone calls, scheduled at the subjects' convenience. At the end of this period, they will revert back to their original insulin pump and complete a questionnaire on the study pump training materials, features and usability.
Interventions
DEVICEMedtronic MiniMed 620G or 640G Insulin Pump
Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
Sponsors
Medtronic Diabetes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
7 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Subject is 7 years or older at time of screening * Subject is current insulin pump user for at least 3 months * Subject has the following Continuous Glucose Monitoring experience as determined by the Investigator: * Has experience and is able to insert/change sensor by herself/himself and * Has experience and can recharge the transmitter and * Has experience and can read sensor data in real-time on her/his pump screen * Subject has signed a Patient Informed Consent form and is willing to comply with the study procedures; * Subject is willing to complete study questionnaires throughout the study * Must have one of the following clinical diagnosis: * Type 1 diabetes, for a minimum of 6 months prior to enrollment * Insulin requiring type 2 diabetes, for a minimum of 6 months prior to enrollment
Exclusion criteria
* Female subject has a positive urine pregnancy screening test. * Female subject who plans to become pregnant during the course of study. If a woman becomes pregnant during participation, she will be withdrawn * Subject has any condition that, in the opinion of the Investigator or qualified Investigational Center staff, may preclude him/her from participating in the study and completing study related procedures. * Subject has impaired vision or hearing problems that could compromise the handling of the device as determined by Investigator or qualified Investigational Center staff * Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter | Four weeks of pump wear | Descriptive summary will be used to characterize the results of the study questionnaires. The questionnaire will use a Likert scale (rating of 1 to 7) to assess overall subject acceptance of the MiniMed 620G, 640G, and Guardian Link Transmitter. A response of 4 or greater on the Likert scale will be considered positive and indicate and product acceptance. |
Countries
Australia, Denmark, Spain, United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Insulin Depedent Diabetics Subject is current insulin pump user and has CGM experience as determined by the investigator. | 55 |
| Total | 55 |
Baseline characteristics
| Characteristic | Insulin Depedent Diabetics |
|---|---|
| Age, Categorical <=18 years | 19 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 36 Participants |
| Age, Continuous | 31.3 years STANDARD_DEVIATION 16.91 |
| Sex: Female, Male Female | 27 Participants |
| Sex: Female, Male Male | 28 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 16 / 55 |
| serious Total, serious adverse events | 0 / 55 |
Outcome results
Primary
User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter
Descriptive summary will be used to characterize the results of the study questionnaires. The questionnaire will use a Likert scale (rating of 1 to 7) to assess overall subject acceptance of the MiniMed 620G, 640G, and Guardian Link Transmitter. A response of 4 or greater on the Likert scale will be considered positive and indicate and product acceptance.
Time frame: Four weeks of pump wear
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Insulin Depedent Diabetics | User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter | 5.88 units on a scale | Standard Deviation 1.32 |